Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
7.00
-0.26 (-3.58%)
At close: Mar 28, 2025, 4:00 PM
6.94
-0.06 (-0.86%)
After-hours: Mar 28, 2025, 7:59 PM EDT

Company Description

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.

The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.
Novavax logo
Country United States
Founded 1987
IPO Date Dec 5, 1995
Industry Biotechnology
Sector Healthcare
Employees 952
CEO John Jacobs

Contact Details

Address:
700 Quince Orchard Road
Gaithersburg, Maryland 20878
United States
Phone 240 268 2000
Website global.novavax.com

Stock Details

Ticker Symbol NVAX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001000694
CUSIP Number 670002401
ISIN Number US6700024010
Employer ID 22-2816046
SIC Code 2836

Key Executives

Name Position
John Charles Jacobs M.B.A. President, Chief Executive Officer and Director
John Joseph Trizzino B.S., M.B.A. President and Chief Operating Officer
James Patrick Kelly C.F.A. Executive Vice President, Chief Financial Officer and Treasurer
Mark Casey Executive Vice President, Chief Legal Officer and Corporate Secretary
Richard P. Crowley Executive Vice President and Chief Operating Officer
Troy Morgan Esq., J.D. Senior Vice President, Deputy General Counsel and Chief Compliance Officer
Erika S. Trahan Associate Director of Investor and Public Relations
Ian J. Watkins Executive Vice President and Chief Human Resources Officer
Silvia Taylor M.B.A. Executive Vice President and Chief Corporate Affairs and Advocacy Officer
Dr. Robert Walker M.D. Senior Vice President and Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 11, 2025 8-K Current Report
Mar 11, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Feb 27, 2025 8-K Current Report
Feb 27, 2025 10-K Annual Report
Feb 5, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Jan 2, 2025 144/A Filing
Dec 30, 2024 8-K Current Report
Dec 26, 2024 144 Filing